

1. Record Nr.	UNINA9910369948503321
Titolo	Novel Therapeutics for Rare Lymphomas // edited by Christopher Dittus
Pubbl/distr/stampa	Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020
ISBN	3-030-25610-3
Edizione	[1st ed. 2020.]
Descrizione fisica	1 online resource (259 pages)
Disciplina	616.99446059 616.99446
Soggetti	Oncology Hematology Oncology
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	The Hematopathology and Diagnostic Challenges of Rare Lymphomas -- Novel Therapeutics in the Management of Waldenstrom Macroglobulinemia -- Immunotherapy in Hodgkin Lymphoma and other CD30+ Lymphomas -- Chronic Lymphocytic Leukemia with Alterations in TP53 -- Mantel Cell Lymphoma -- Current and Emerging Treatment Strategies from Primary Mediastinal B-Cell Lymphoma -- Plasmablastic Lymphoma and Primary Effusion Lymphoma -- Novel Agents in Primary Central Nervous System Lymphoma -- Adult T-Cell Leukemia/Lymphoma -- Extranodal NK/T-Cell Lymphoma -- Anaplastic Large Cell Lymphoma -- Enteropathy-Associated T-Cell Lymphomas -- Hepatosplenic T-Cell Lymphoma -- Cutaneous T-Cell Lymphoma: Mycosis Fungoides and Sezary Syndrom.
Sommario/riassunto	This comprehensive volume reviews the clinical presentation, diagnosis, and treatment approach to rare lymphomas. There is particular emphasis placed on new diagnostic approaches, novel chemotherapy combinations, and treatment modalities with novel therapeutics. It highlights research advances in a group of diseases that are often overlooked, and serves as a single repository of information on the most recent advances in targeted small molecule inhibitors, monoclonal antibodies, immunotherapy, and CAR-T therapy as they

pertain to rare types of lymphoma. Written for practicing oncologists, hematologists, fellows, and residents, *Novel Therapeutics for Rare Lymphomas* covers rare subtypes of lymphoma, including indolent and aggressive T-cell lymphomas and B-cell lymphomas.
